Appeals Court Revives Tylenol Autism Lawsuits Against Kenvue
KVUE sits 37% above its 52-week low of $14.02.
Summary
A federal appeals court revived hundreds of private lawsuits alleging that Tylenol use during pregnancy causes autism and ADHD. The 2nd U.S. Circuit Court of Appeals ruled that a lower court improperly excluded expert testimony from parents, sending the cases back for further proceedings. This is a significant legal setback for Kenvue, as the litigation had been largely dormant. The decision reopens a major liability overhang for the company, which relies on Tylenol as a core brand. The scope of potential damages is substantial given the number of plaintiffs and the severity of the alleged injuries. No trial dates have been set, but the ruling increases the likelihood of costly settlements or judgments.
At the time of this announcement, KVUE was trading at $19.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37B. The 52-week trading range was $14.02 to $22.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.